Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer
02/07/2013 04:01 PM EST
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.
0 comments :
Post a Comment